Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LUNG Stock Forecast 2025-2026
$3.11
Current Price
$129.43M
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LUNG Price Targets
+446.6%
To High Target of $17.00
+285.9%
To Median Target of $12.00
+92.9%
To Low Target of $6.00
LUNG Price Momentum
-9.3%
1 Week Change
-39.8%
1 Month Change
-61.5%
1 Year Change
-54.2%
Year-to-Date Change
-66.8%
From 52W High of $9.37
+4.7%
From 52W Low of $2.97
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Pulmonx (LUNG) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LUNG and similar high-potential opportunities.
Latest LUNG Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, LUNG has a bullish consensus with a median price target of $12.00 (ranging from $6.00 to $17.00). Currently trading at $3.11, the median forecast implies a 285.9% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 446.6% upside. Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 92.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LUNG Analyst Ratings
5
Buy
2
Hold
0
Sell
LUNG Price Target Range
Low
$6.00
Average
$12.00
High
$17.00
Current: $3.11
Latest LUNG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LUNG.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $4.15 |
| May 1, 2025 | Canaccord Genuity | Jon Young | Buy | Maintains | $15.00 |
| May 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $17.00 |
| May 1, 2025 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $9.00 |
| Mar 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $17.00 |
| Mar 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $17.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Neutral | Downgrade | $7.50 |
| Dec 11, 2024 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $8.00 |
| Oct 31, 2024 | Stifel | Rick Wise | Buy | Maintains | $16.00 |
| Aug 1, 2024 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $10.00 |
| Aug 1, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $12.00 |
| Aug 1, 2024 | Canaccord Genuity | Jon Young | Buy | Maintains | $16.00 |
| Jun 4, 2024 | Lake Street | Frank Takkinen | Buy | Initiates | $12.00 |
| May 2, 2024 | Canaccord Genuity | Jon Young | Buy | Maintains | $15.00 |
| Apr 3, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $17.00 |
| Feb 23, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $17.00 |
| Feb 23, 2024 | Wells Fargo | Larry Biegelsen | Equal-Weight | Downgrade | $14.00 |
| Feb 22, 2024 | Stifel | Rick Wise | Buy | Maintains | $17.00 |
| Feb 22, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $16.00 |
| Feb 22, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $17.00 |
Pulmonx Corporation (LUNG) Competitors
The following stocks are similar to Pulmonx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pulmonx Corporation (LUNG) Financial Data
Pulmonx Corporation has a market capitalization of $129.43M with a P/E ratio of -2.1x. The company generates $87.47M in trailing twelve-month revenue with a -65.3% profit margin.
Revenue growth is +19.5% quarter-over-quarter, while maintaining an operating margin of -64.6% and return on equity of -60.7%.
Valuation Metrics
Market Cap
$129.43M
Enterprise Value
$94.66M
P/E Ratio
-2.1x
PEG Ratio
-2.0x
Price/Sales
1.5x
Growth & Margins
Revenue Growth (YoY)
+19.5%
Gross Margin
+72.5%
Operating Margin
-64.6%
Net Margin
-65.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+70.8%
Current Ratio
5.0x
Debt/Equity
73.3x
ROE
-60.7%
ROA
-22.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pulmonx Corporation (LUNG) Business Model
About Pulmonx Corporation
What They Do
Develops minimally invasive treatments for lung disorders.
Business Model
Pulmonx Corporation generates revenue by developing and commercializing medical technologies, specifically for treating chronic obstructive pulmonary disease (COPD). The company focuses on innovative products such as the Zephyr Valve, which offers a less invasive alternative to traditional surgical options for patients with severe emphysema.
Additional Information
Headquartered in Redwood City, California, Pulmonx collaborates with healthcare providers globally to broaden the availability of its advanced treatment solutions. The company is well-positioned in the growing medical device industry, especially as the demand for effective treatments for chronic lung diseases continues to rise.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,859
CEO
Mr. Steven S. Williamson
Country
Japan
IPO Year
2020
Website
www.nisshin.nipponsteel.comPulmonx Corporation (LUNG) Latest News & Analysis
Latest News
Quick Summary
Pulmonx Corporation (NASDAQ:LUNG) will hold its Q1 2025 Earnings Conference Call on April 30, 2025, at 4:30 PM ET. Key executives will participate in the call.
Why It Matters
The earnings call will provide insights into Pulmonx's financial performance and strategic direction, influencing market sentiment and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pulmonx Corporation (Nasdaq: LUNG) reported its first-quarter 2025 financial results for the period ending March 31, 2025. Further details on performance are pending.
Why It Matters
Pulmonx's Q1 2025 financial results could indicate growth or challenges in its operations, impacting stock performance and investor sentiment in the lung disease treatment sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pulmonx Corporation (LUNG) reported a quarterly loss of $0.36 per share, slightly better than the Zacks Consensus Estimate of $0.37. The loss matches the previous year's figure.
Why It Matters
Pulmonx's narrower quarterly loss than expected may indicate improving operational efficiency, potentially boosting investor confidence and impacting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Pulmonx Corporation (Nasdaq: LUNG) will present at the Bank of America Securities 2025 Health Care Conference on May 14, 2025, at 9:35 AM PT in Las Vegas.
Why It Matters
Pulmonx's presentation at a major health care conference may signal strategic developments, influencing investor sentiment and potential stock performance in the medical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
EDAP Appoints Glen French to Board of Directors
2 months ago
Quick Summary
EDAP TMS SA announced the appointment of Glen French to its Board of Directors, as confirmed by Interim Chairman Dr. Lance Willsey, on March 3, 2025.
Why It Matters
The appointment of Glen French to EDAP's Board may signal strategic shifts or enhanced governance, potentially impacting company performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pulmonx Corporation (NASDAQ:LUNG) will hold its Q4 2024 earnings conference call on February 19, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters
The earnings call will provide insights into Pulmonx's financial performance and strategy, impacting stock valuation and investor sentiment. Key analysts' questions may reveal market expectations.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About LUNG Stock
What is Pulmonx Corporation's (LUNG) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Pulmonx Corporation (LUNG) has a median price target of $12.00. The highest price target is $17.00 and the lowest is $6.00.
Is LUNG stock a good investment in 2025?
According to current analyst ratings, LUNG has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LUNG stock?
Wall Street analysts predict LUNG stock could reach $12.00 in the next 12 months. This represents a 285.9% increase from the current price of $3.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pulmonx Corporation's business model?
Pulmonx Corporation generates revenue by developing and commercializing medical technologies, specifically for treating chronic obstructive pulmonary disease (COPD). The company focuses on innovative products such as the Zephyr Valve, which offers a less invasive alternative to traditional surgical options for patients with severe emphysema.
What is the highest forecasted price for LUNG Pulmonx Corporation?
The highest price target for LUNG is $17.00 from Jason Kolbert at D. Boral Capital, which represents a 446.6% increase from the current price of $3.11.
What is the lowest forecasted price for LUNG Pulmonx Corporation?
The lowest price target for LUNG is $6.00 from Larry Biegelsen at Wells Fargo, which represents a 92.9% increase from the current price of $3.11.
What is the overall LUNG consensus from analysts for Pulmonx Corporation?
The overall analyst consensus for LUNG is bullish. Out of 14 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are LUNG stock price projections?
Stock price projections, including those for Pulmonx Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 3:37 AM UTC